Omeros Corporation (OMER) Tuesday said that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Prescription Drug User Fee Act (PDUFA) target action date or a decision from the regulator is expected in late September this year.
Omeros is also planning to submit a marketing authorization application (MAA) to the European Medicines Agency for narsoplimab in TA-TMA later this quarter.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.